莪术醇对人卵巢癌SKOV3细胞增殖、迁移、侵袭及凋亡的影响

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1290 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：探讨莪术醇对人卵巢癌SKOV3细胞增殖、迁移、侵袭及凋亡的影响。方法：采用CCK-8法检测不同浓度（5、10、25、50、100 μmol/L）莪术醇，0 μmol/L莪术醇为对照组，干预SKOV3细胞24 h、48 h的增殖抑制率，并计算IC50值；划痕实验和Transwell小室法分别检测细胞的迁移和侵袭能力，流式细胞术检测细胞凋亡率；Western blot法检测莪术醇及PI3K/AKT通路阻断剂LY294002对细胞PI3K、p-PI3K、AKT、p-AKT蛋白表达的影响。结果：莪术醇对SKOV3细胞的增殖有明显抑制作用，呈浓度依赖性但不呈现时间依赖性，IC50值为48 μmol/L；莪术醇能明显抑制SKOV3细胞的迁移与侵袭，促进其凋亡（均P＜0.01），降低细胞PI3K、AKT总蛋白表达（均P＜0.05），显著降低其活化形式p-PI3K、p-AKT的表达（均P＜0.01）；莪术醇与LY294002联用后表现出良好的协同作用，较单独用莪术醇时下调p-PI3K、p-AKT蛋白更为显著（P＜0.05）。结论：莪术醇能抑制SKOV3细胞增殖、迁移及侵袭，并诱导其凋亡，其作用机制与抑制PI3K/AKT通路有关。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	戴凌虹
	孙云
	陈祥艳

关键词 ：莪术醇, 卵巢癌, 增殖, 迁移, 侵袭, PI3K/AKT通路

Abstract：Objective: To investigate the effects of curcumol on proliferation, migration, invasion and apoptosis of human ovarian cancer SKOV3 cells. Methods: The CCK-8 method was used to detect the inhibition rate of SKOV3 cells at different concentrations (0, 5, 10, 25, 50, 100 μmol/L) for 24 h and 48 h, and the IC50 value was calculated. The scratch test and Transwell chamber method were used to detect the cells. Migration and invasion ability, apoptosis rate was detected by flow cytometry, Western blot was used to detect the effects of curcumol and PI3K/AKT pathway blocker LY294002 on the expression of PI3K, p-PI3K, AKT and p-AKT proteins. Results: Curcumol significantly inhibited the proliferation of SKOV3 cells in a concentration-dependent but time-independent manner, with an IC50 value of 48 μmol/L. Meanwhile, curcumol significantly inhibited the migration and invasion of SKOV3 cells and promoted apoptosis (P<0.01). The expression of total protein PI3K and AKT was decreased (P<0.05), and the expression of phosphorylated forms p-PI3K and p-AKT was significantly decreased (P<0.01). The combination of curcumol and LY294002 showed a good synergistic effect, which was more obvious than that of the curcumol alone in the down-regulation of p-PI3K, p-AKT (P<0.05). Conclusion: Curcumol can inhibit the proliferation, migration and invasion of SKOV3 cells and induce apoptosis, which is related to the inhibition of PI3K/AKT pathway.

Key words： curcumol ovarian cancer proliferation migration invasion PI3K/AKT pathway

收稿日期: 2018-10-30

基金资助:温州市科技计划项目（Y20160348）。

作者简介: 戴凌虹（1981-），女，浙江温州人，副主任医师。

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2019/V49/I10/740

[1] AI Z, LU Y, QIU S, et al. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism[J]. Cancer Letters, 2016, 373(1): 36-44.
[2] LIN Y H, CHEN B Y, LAI W T, et al. The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells[J]. Naunyn Schmiedebergs Arch Pharmacol, 2015, 388(1): 19-31.
[3] KIGAWA J. New strategy for overcoming resistance to chemotherapy of ovarian cancer[J]. Yonago Acta Med, 2013, 56(2): 43-50.
[4] NING L, MA H, JIANG Z, et al. Curcumol suppresses breast cancer cell metastasis by inhibiting MMP-9 via JNK1/2 and Akt-dependent NF-κB signaling pathways[J]. Integr Cancer Ther, 2016, 15(2): 216-225.
[5] 潘睿. 中国慢性病前瞻性研究队列恶性肿瘤发病与死亡分析[D]. 南京: 南京医科大学, 2017.
[6] JANUCHOWSKI R, ZAWIERUCHA P, RUCIŃSKI M,
et al. Microarray-based detection and expression analysis of extracellular matrix proteins in drug-resistant ovarian cancer cell lines[J]. Oncol Rep, 2014, 32: 1981-1990.
[7] 秦铁城, 文海斌, 陈珮, 等. 莪术醇抗肿瘤研究进展[J]. 现代中西医结合杂志, 2013, 22(18): 2043-2045.
[8] 汤欣, 韩凤娟, 李威, 等. 莪术醇对人卵巢癌SKOV3细胞株JAK2/STAT3信号通路影响的研究[J]. 中国妇产科临床杂志, 2013, 14(1): 43-46.
[9] BOMMAREDDY A, CRISAMORE K, FILLMAN S, et al.
Survivin down-regulation by α-santalol is not mediated through PI3K-AKT pathway in human breast cancer cells[J].
Anticancer Res, 2015, 35(10): 5353-5357.
[10] 朱雪洁, 周璐璐, 朱雪琼. 晚期糖基化终末产物受体在妇科恶性肿瘤中的研究进展[J]. 温州医科大学学报, 2017, 47(10): 777-781.
[11] 韦立群, 李清, 甘嘉亮, 等. 迷迭香酸衍生物RAD-9通过PI3K/AKT和p38 MAPK信号通路诱导胃癌MGC-803细胞凋亡[J]. 中国药理学通报, 2018, 34(2): 256-260.
[12] YANG M, WANG H, ZHOU M. The natural compound sulforaphene, as a novel anticancer reagent, targeting PI3K-AKT signaling pathway in lung cancer[J]. Oncotarget, 2016, 7(47): 76656-76666.